Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MAGELLAN HEALTH, INC.

(MGLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CVS Health CEO Larry Merlo to step down next year

11/06/2020 | 05:50pm EDT
Larry Merlo, president and CEO of CVS Health, discusses the future of health care delivery

(Reuters) - CVS Health Corp Chief Executive Officer Larry Merlo will retire after a decade-long tenure at the helm of the company during which he led the $69 billion acquisition of one of the oldest U.S. health insurer, Aetna.

Karen Lynch, who was with Aetna at the time of the acquisition in 2018, will succeed Merlo in February, CVS said on Friday. Lynch, 57, has been with Aetna for eight years and was previously president of Magellan Health Services.

The CVS-Aetna merger was sixty-four-year-old Merlo's vision who wanted to bring more medical services and testing into CVS' HealthHub stores nationwide. The leading pharmacy operator aims to have 600 of those stores by the end of the year and 1,500 next year.

"Investors will likely view this transition positively as Karen Lynch is well respected by the investor community," Evercore ISI analysts said in a client note.

Shares of the company, which raised its full-year profit forecast on Friday after beating analysts' estimates for quarterly earnings, rose 4.1%.

The company said it has administered more than 6 million COVID-19 tests since March, and expects to play an "important role" in COVID-19 vaccinations, once vaccines are available; a handful are in late-stage testing.

CVS and rival Walgreens have partnered with the U.S. government to offer on-site vaccinations for residents of care home and assisted living facilities. CVS is also expected to provide vaccinations in its pharmacies.

In the third quarter, the company saw same-store pharmacy sales rise 6.7%, helping it beat Wall Street estimates for profit.

CVS earned $1.66 per share on an adjusted basis, beating analysts' average estimate of $1.33 per share, according to IBES data from Refinitiv.

CVS raised its 2020 adjusted earnings per share forecast to $7.35 to $7.45 from $7.14 to $7.27 previously.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

By Manas Mishra and Caroline Humer


ę Reuters 2020
All news about MAGELLAN HEALTH, INC.
09/15MAGELLAN HEALTH : Rx Management's AIDS Drug Assistance Program Center of Excelle..
BU
09/01MAGELLAN HEALTH : Provides Free Consultation Services and Referrals to Local Com..
BU
08/30MAGELLAN HEALTH : Growth and Innovation Division at Magellan Health Announces Ne..
BU
08/30Magellan Health, Inc. Announces Executive Appointments
CI
08/26MAGELLAN HEALTH : Unit Launches Video Game Platform for Children's Mental Health
MT
08/26MAGELLAN HEALTH : Healthcare Launches Clinically Proven Video Game Solution to S..
BU
08/24MAGELLAN HEALTH : Healthcare Offers Ecosystem of Services for Suicide Prevention
BU
08/18MAGELLAN HEALTH : Healthcare Launches eMbolden Resilience Program
BU
08/05MAGELLAN HEALTH : Management's Discussion and Analysis of Financial Condition an..
AQ
08/05MAGELLAN HEALTH : Q2 Earnings Snapshot
AQ
More news
Analyst Recommendations on MAGELLAN HEALTH, INC.
More recommendations
Financials (USD)
Sales 2021 4 808 M - -
Net income 2021 35,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 76,6x
Yield 2021 -
Capitalization 2 485 M 2 485 M -
Capi. / Sales 2021 0,52x
Capi. / Sales 2022 0,48x
Nbr of Employees 9 000
Free-Float 46,2%
Chart MAGELLAN HEALTH, INC.
Duration : Period :
Magellan Health, Inc. Technical Analysis Chart | MGLN | US5590792074 | MarketScreener
Technical analysis trends MAGELLAN HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 94,62 $
Average target price 95,00 $
Spread / Average Target 0,40%
EPS Revisions
Managers and Directors
Kenneth J. Fasola Chief Executive Officer & Director
James E. Murray President & Chief Operating Officer
David Patrick Bourdon Chief Financial Officer
Steve J. Shulman Chairman
Caroline Carney Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MAGELLAN HEALTH, INC.14.22%2 485
UNITEDHEALTH GROUP19.81%396 176
ANTHEM, INC.18.20%92 533
CIGNA CORPORATION-1.23%69 933
HUMANA INC.-0.60%52 403
CENTENE CORPORATION7.68%37 688